Study hopes to inform the research agenda and help future research to focus on the questions that are most important to key stakeholders The global consumption of psychiatric… read more.
Intra-Cellular Therapies, Inc. announced positive results from Study 304 evaluating the efficacy and safety of lumateperone 42 mg for the prevention of relapse in adult patients with schizophrenia…. read more.
Researchers report that patients treated with semaglutide have achieved a significantly lower risk of developing Alzheimer’s disease compared to those exposed to seven other anti-diabetic medications, including other… read more.
Attention deficit/hyperactivity disorder – also known as ADHD – is typically thought of as a childhood condition. But more adults are realizing that their struggles with attention, focus… read more.
Prescribing rates for stimulants that treat attention-deficit/hyperactivity disorder (ADHD) have increased significantly over the past decade, with some of the largest increases reported during the COVID-19 pandemic. A… read more.
A new study reveals that young patients treated with psychiatric medications receive potentially dangerous combinations with concerning frequency. Researchers from Rutgers Health and other institutions analyzed New York… read more.
Misconceptions about dyslexia are held by professionals who assess children for the learning difficulty, according to a new study which calls for evidence-based standardised assessment procedures. The research,… read more.
U.S. pediatric inpatient psychiatric bed capacity did not change 2017 – 2020, despite increases in pediatric mental health emergency visits, according to a study published in JAMA Pediatrics. Researchers… read more.
A new scientific review of 148 studies enrolling over 4.3 million adult chronic pain patients treated with prescription opioid painkillers has found that nearly one in ten patients… read more.
Research led by the University of Southampton has found that medications play an important role in improving the quality of life of people with ADHD, but the authors… read more.
Indivior has discontinued sales and marketing for its schizophrenia drug Perseris. This last decision, prompted by increased payor management impacts, is expected to make the product financially unviable… read more.
A large retrospective analysis of the cognitive effects of various antidiabetic treatments has disclosed that the risks of dementia and Alzheimer’s disease (AD) were significantly lower in patients… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
